RPG Life Sciences Appoints New CFO, Transfers API Business to Subsidiary
RPG Life Sciences appointed Mr. Amol Lone as CFO effective December 15, 2025. The company will incorporate "RPG Active Pharma Limited" to house its API business, transferring it for an estimated ₹50 crore. Up to ₹105 crore will be invested in the subsidiary. The transfer is expected to be completed by March 31, 2026.
The appointment of a key managerial personnel and the restructuring of a significant business segment (API) are likely to have a medium-term impact on the company's strategic direction and financial performance.
The appointment of a new CFO and the strategic transfer and capitalization of the API business into a dedicated subsidiary are positive developments for operational focus and future growth.
RPG Life Sciences Limited announced a significant board meeting outcome on December 15, 2025. The Board of Directors unanimously approved the appointment of Mr. Amol Lone as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company, effective from December 15, 2025. Mr. Lone brings over two decades of experience in corporate finance, financial planning, taxation, and strategic decision-making, holding qualifications as a chartered accountant and an MBA in International Business.
Furthermore, the company resolved to incorporate a new wholly owned subsidiary, to be named "RPG Active Pharma Limited" or a similar approved name. This subsidiary will focus on the manufacture and marketing of active pharmaceutical ingredients (API) and related pharmaceutical products. The API business of RPG Life Sciences Limited will be transferred to this new subsidiary as a going concern, subject to necessary statutory and regulatory approvals.
The company plans to invest up to ₹105 crore in the new subsidiary in one or more tranches for capitalization and business operations. The API business transferred represented ₹90.24 crore in revenue for FY25, approximately 13.8% of the company's turnover, with a net worth of ₹90.61 crore as of March 31, 2025. The transfer agreement is expected to be executed by February 28, 2026, with the transaction completion targeted by March 31, 2026. The consideration for the transfer is estimated at approximately ₹50 crore, to be determined based on the business transfer agreement and subject to customary adjustments. This transfer is considered a related party transaction as it involves a wholly owned subsidiary and will be conducted at book value.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.